Skip to main
ANAB

AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio (ANAB) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

AnaptysBio is a promising biotechnology company with multiple drug candidates in the pipeline, such as rosnilimab and ANB032, which have shown positive results in clinical trials for various autoimmune and inflammatory diseases. The company's strategic partnerships and strong financial position, with a cash and cash equivalents balance of $395.7 million as of December 2020, provide them with the necessary resources to continue their research and development efforts. However, there are risks associated with potential regulatory hurdles and competition in the market. Overall, AnaptysBio's innovative approach and solid financial foundation make it an attractive investment for those seeking long-term growth potential in the biotech industry.

Bears say

AnaptysBio is currently facing several key risks that could significantly impact the company's future revenue potential. These risks include ongoing litigation with GSK over the Jemperli royalty stream, potential slowdown in commercial uptake of Jemperli, increased competition in the PD-1/PD-L1 market, and potential disappointing clinical trial results. Additionally, the company's revenue is heavily reliant on Jemperli, with no other product candidates approved for commercialization. If any of these risks were to materialize, it could lead to a significant decrease in the company's revenue and overall valuation.

AnaptysBio (ANAB) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AnaptysBio (ANAB) Forecast

Analysts have given AnaptysBio (ANAB) a Buy based on their latest research and market trends.

According to 10 analysts, AnaptysBio (ANAB) has a Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $81.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $81.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AnaptysBio (ANAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.